Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 16/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.51 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930665 | 0.95 | LRRK2 (0.53) | LRRK2DYRK1AJAK2MAP3K9MKNK2 | |
| Trifluoroacetic Acid SCHEMBL2933461 | 0.92 | DYRK1A (0.48) | LRRK2DYRK1ATTK | |
| SCHEMBL14294231 | 0.88 | LRRK2 (0.49) | LRRK2TTK | |
| SCHEMBL2930788 | 0.86 | KDR (0.50) | LRRK2DYRK1ATTK | |
| SCHEMBL2929459 | 0.84 | VCP (0.45) | LRRK2DYRK1ATTK | |
| SCHEMBL2926010 | 0.84 | LRRK2 (0.53) | LRRK2DYRK1ATTK | |
| SCHEMBL2927025 | 0.84 | KDR (0.47) | LRRK2DYRK1ATTK | |
| Trifluoroacetic Acid SCHEMBL2928635 | 0.83 | DYRK1A (0.47) | LRRK2DYRK1ATTK | |
| SCHEMBL2928684 | 0.83 | LRRK2 (0.44) | LRRK2DYRK1ATTK | |
| SCHEMBL2934905 | 0.83 | TTK (0.46) | LRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | LRRK2 309/4885DYRK1A 498/4885TTK 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.